Loading stock data…
Cellebrite DI Ltd (CLBT)
$11.45
Market ClosedLast close Sep 8
Cellebrite DI Ltd.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cellebrite DI Ltd. in the Technology sector is trading at $11.45 with a market capitalization of $3.2B. Wall Street consensus targets $15.36 (7 analysts), implying a +34.1% move over the next 12 months. The stock is currently near its 52-week low of $9.58, remaining 21.9% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +34.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $128.30M↓ | $128.82M↑ | $126.03M↑ | $113.28M↑ | $107.55M |
| Gross Profit | $105.88M↓ | $109.13M↑ | $105.72M↑ | $95.60M↑ | $90.06M |
| Operating Income | $9.12M↓ | $20.80M↑ | $18.99M↑ | $14.42M↑ | $12.27M |
| Net Income | $10.94M↓ | $21.26M↑ | $20.19M↑ | $19.48M↑ | $17.40M |
Peer Comparison
AAPLMSFTGOOGL
Fundamentals
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, ext...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.08%
Volume
Today's trading volume
3.78M
Recent News
Cellebrite (CLBT): CEO Shift and Guidance Cuts Contrast With Surging AI and FedRAMP Gains
On August 13, Cellebrite (NASDAQ:CLBT) named a new chief executive and trimmed its full-year outlook on the same morning. Shiven Ramji stepped in as CEO effective that day, replacing Tom Hogan, while the company lowered its 2026 revenue and ARR targets after several large government deals slipped past the quarter. Management highlighted positive growth drivers […]
Cellebrite (CLBT) Q2 2026 Earnings Call Transcript
CEO Ramji cites elongated sales cycles and lower pricing gains from product migrations.
Cellebrite’s (CLBT) Compounding Track Record Demands Enterprise Software Re-Rating
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating progress from the first quarter. Key changes to the portfolio will include lower concentration and increased investments with near-term catalysts, […]
Cellebrite DI (CLBT) Cuts Guidance And Changes CEO, Is The Stock Now Cheap?
Cellebrite DI (CLBT) has come under fresh scrutiny after its August 13 Q2 2026 earnings report, guidance cut, and CEO transition, with Levi & Korsinsky launching an investigation following a sharp post results share price decline. See our latest analysis for Cellebrite DI. Cellebrite DI’s latest earnings miss, guidance reset and CEO change have coincided with sharp selling, with the share price down 29.18% over one day and 33.25% over 30 days, while the 3 year total shareholder return remains...
Does Cellebrite DI’s Lowered 2026 Outlook and New CEO Reset Its AI Narrative (CLBT)?
In August 2026, Cellebrite DI Ltd. reported second-quarter results showing revenue of US$131.14 million and net income of US$6.37 million, while lowering its full-year 2026 revenue guidance to US$555 million–US$561 million and announcing Shiven Ramji’s appointment as CEO, succeeding Thomas E. Hogan. The combination of reduced revenue expectations, softer profitability, and a leadership transition raises questions about how quickly Cellebrite can convert its product and AI investments,...